The trial includes 30,000 U.S. participants, and is investigating the use of the COVID-19 vaccine candidate messenger RNA (mRNA)-1273 at a dose of 100 µg. It was designed to evaluate individuals at higher risk of severe COVID-19 disease and included more than 7,000 U.S. adults over the age of 65. Interim data will be submitted to the Data Safety Monitoring Board (DSMB).

Moderna developed the vaccine candidate in collaboration with the U.S. National Institute of Allergy and Infectious Diseases (NIAID) Vaccine Research Center, it said. The research and development of mRNA-1273 is supported by $955 million in federal funding from the Biomedical Advanced Research and Development Authority (BARDA). The U.S. government has committed up to $1.5 billion to purchase supply of the vaccine once it has been validated, according to Moderna.

If successful, COVID-19 vaccines could be worth $27B
Vaccines are considered one of the most effective public health measures preventing diseases in the modern world. They could also be very profitable endeavors,...

Moderna gets nod from EMA to submit marketing authorization
Moderna has received written confirmation from the European Medicines Agency (EMA) that messenger RNA (mRNA)-1273, the company's COVID-19 vaccine candidate,...

Moderna secures $56M for mobile vaccine manufacturing
Moderna has received $56 million from the Defense Advanced Research Projects Agency to fund manufacturing of nucleic acid vaccines and therapeutics.

Moderna touts positive vaccine results in older populations
Results from Moderna's phase I clinical trial indicated that its candidate for a COVID-19 vaccine, messenger RNA (mRNA)-1273, is well-tolerated and generates...

Canada orders 20M doses of Moderna COVID-19 vaccine
The Canadian government increased its confirmed order commitment to 20 million doses of messenger RNA (mRNA)-1273, Moderna's COVID-19 vaccine candidate.